You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit

    SBC: SILICON CURES LLC            Topic: NINR

    PROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: INOVODEL, INC.            Topic: NHLBI

    SUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a novel sensor for the real-time measurement of mitral coaptation force

    SBC: MitralPint Inc.            Topic: NHLBI

    Project Summary The proposed project will develop a breakthrough endovascular sensor technology to allow for real-time quantification of the mitral coaptation force (MCF) of the mitral valve during both open and percutaneous mitral valve repair (MVR). Mitral regurgitation (MR) is the most common heart valve disorder in the U.S. population, with over 2 million individuals affected. Current methods ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text

    SBC: GRAYRAIN, LLC            Topic: NCATS

    PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Structure-based computational engineering of saCas9 PAM requirement

    SBC: ATGC Inc.            Topic: 400

    ABSTRACT SaCas9 is a major gene editing nuclease that is preferred for in vivo applications thanks to its relatively smaller size compared to that of spCas9. One limiting factor for the use of saCas9 is its strict PAM requirement of NNGRRT. In addition, there are limited efforts to reduce saCas9’s off-target editing rates. In Aim 1, we propose a computational approach to relax saCas9’s PAM req ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Therapeutic Agents Targeting Cryptococcal Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Cryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Treatment for Alcohol-associated Liver Disease

    SBC: MITOTHERAPEUTIX, LLC            Topic: 350

    Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of preventable morbidity and mortality. In the U.S., alcohol abuse impacts over 10 million individuals ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government